SI1703893T1 - Nova protitelesa proti il in uporaba le teh - Google Patents

Nova protitelesa proti il in uporaba le teh

Info

Publication number: SI1703893T1
Authority: SI; Slovenia
Prior art keywords: allergic; antibodies; asthma; glycosylated; relates
Prior art date: 2003-12-23

Application number

SI200431888T

Other languages

English (en)

Inventor

Sek Chung Fung

Matthew Moyle

Mason Lu

Changning Yan

Sanjaya Singh

Dan Huang

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-23

Filing date

2004-12-23

Publication date

2012-07-31

2004-12-23 Application filed by Genentech Inc filed Critical Genentech Inc

2012-07-31 Publication of SI1703893T1 publication Critical patent/SI1703893T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI200431888T 2003-12-23 2004-12-23 Nova protitelesa proti il in uporaba le teh SI1703893T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53213003P	2003-12-23	2003-12-23
EP04815562A EP1703893B1 (en)	2003-12-23	2004-12-23	Novel anti-il 13 antibodies and uses thereof
PCT/US2004/043501 WO2005062967A2 (en)	2003-12-23	2004-12-23	Novel anti-il 13 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SI1703893T1 true SI1703893T1 (sl)	2012-07-31

Family

ID=34738751

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SI200431888T SI1703893T1 (sl)	2003-12-23	2004-12-23	Nova protitelesa proti il in uporaba le teh
SI200432525T SI3718564T1 (sl)	2003-12-23	2004-12-23	Nova protitelesa proti il 13 in uporaba le-teh
SI200432492T SI2805728T1 (sl)	2003-12-23	2004-12-23	Nova protitelesa proti il 13 in uporabe le-teh
SI200431935T SI1711528T1 (sl)	2003-12-23	2004-12-23	Zdravljenje raka z novimi anti-il 13 monoklonskimi protitelesi

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SI200432525T SI3718564T1 (sl)	2003-12-23	2004-12-23	Nova protitelesa proti il 13 in uporaba le-teh
SI200432492T SI2805728T1 (sl)	2003-12-23	2004-12-23	Nova protitelesa proti il 13 in uporabe le-teh
SI200431935T SI1711528T1 (sl)	2003-12-23	2004-12-23	Zdravljenje raka z novimi anti-il 13 monoklonskimi protitelesi

Country Status (23)

Country	Link
US (10)	US7674459B2 (sl)
EP (6)	EP3718564B1 (sl)
JP (5)	JP4851944B2 (sl)
KR (5)	KR101627588B1 (sl)
CN (4)	CN1898264A (sl)
AT (1)	ATE552850T1 (sl)
AU (1)	AU2004308494B2 (sl)
CA (2)	CA2550651C (sl)
CY (2)	CY1113009T1 (sl)
DK (4)	DK3718564T3 (sl)
ES (5)	ES2775204T3 (sl)
FI (1)	FI3718564T3 (sl)
HR (3)	HRP20120376T1 (sl)
HU (2)	HUE064610T2 (sl)
IL (2)	IL176042A (sl)
LT (2)	LT3718564T (sl)
MX (1)	MX361174B (sl)
PL (4)	PL2805728T3 (sl)
PT (3)	PT1703893E (sl)
RU (3)	RU2487887C2 (sl)
SG (4)	SG10201404273QA (sl)
SI (4)	SI1703893T1 (sl)
WO (2)	WO2005062972A2 (sl)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7883704B2 (en) *	1999-03-25	2011-02-08	Abbott Gmbh & Co. Kg	Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
DK3718564T3 (da) *	2003-12-23	2023-11-06	Genentech Inc	Nye anti-IL-13-antistoffer og anvendelser
WO2005079755A2 (en) *	2004-02-12	2005-09-01	Nektar Therapeutics	Interleukin-13 antagonist powders, spray-dried particles, and methods
DE602005018325D1 (de)	2004-02-19	2010-01-28	Genentech Inc	Antikörper mit korrigierten cdr
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
JP2008520684A (ja) *	2004-11-17	2008-06-19	アブジェニックス・インコーポレーテッド	Ｉｌ−１３に対する完全ヒトモノクローナル抗体
WO2007036745A2 (en)	2005-09-30	2007-04-05	Medimmune Limited	Interleukin-13 antibody composition
WO2007044450A2 (en) *	2005-10-06	2007-04-19	Baylor Research Institute	Compositions and methods for the treatment of cancer
US20070202106A1 (en) *	2005-10-06	2007-08-30	Baylor Research Institute	Compositions and methods for the treatment of cancer
EP1957530A2 (en)	2005-10-21	2008-08-20	Novartis AG	Human antibodies against il13 and therapeutic uses
DK1976877T4 (en)	2005-11-30	2017-01-16	Abbvie Inc	Monoclonal antibodies to amyloid beta protein and uses thereof
GB0600488D0 (en) *	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
BRPI0710572A2 (pt) *	2006-01-24	2013-01-08	Domantis Ltd	ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
PL2059533T3 (pl)	2006-08-30	2013-04-30	Genentech Inc	Przeciwciała wieloswoiste
KR101625961B1 (ko) *	2006-09-08	2016-05-31	애브비 바하마스 리미티드	인터루킨-13 결합 단백질
CA2675233A1 (en)	2007-01-16	2008-07-24	Abbott Laboratories	Methods for treating psoriasis
RU2009140134A (ru) *	2007-04-23	2011-05-27	Вайет (Us)	Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
WO2008140455A1 (en) *	2007-05-15	2008-11-20	Tanox, Inc.	Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
US8183982B2 (en)	2007-08-14	2012-05-22	Infineon Technologies Ag	System including reply signal that at least partially overlaps request
US20100291677A1 (en)	2007-08-24	2010-11-18	Keio University	Reducer of immunosuppression by tumor cell and antitumor agent using the same
EP2050764A1 (en) *	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
TWI461210B (zh)	2008-03-18	2014-11-21	Abbvie Inc	治療牛皮癬的方法
CN102232113A (zh) *	2008-03-31	2011-11-02	健泰科生物技术公司	用于治疗和诊断哮喘的组合物和方法
JP2012506695A (ja)	2008-08-20	2012-03-22	ヤンセンバイオテツク，インコーポレーテツド	改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
WO2010027981A1 (en)	2008-09-03	2010-03-11	Genentech, Inc.	Multispecific antibodies
CA2744588A1 (en) *	2008-11-26	2010-06-03	Glaxo Group Limited	Ligands that bind il-13
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RS63430B1 (sr)	2010-10-01	2022-08-31	Modernatx Inc	Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP3447491A3 (en) *	2010-12-16	2019-06-05	F. Hoffmann-La Roche AG	Diagnosis and treatments relating to th2 inhibition
DK2663579T3 (en)	2011-01-14	2017-07-31	Univ California	THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
RU2013140685A (ru)	2011-02-04	2015-03-10	Дженентек, Инк.	ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
AR085911A1 (es)	2011-03-16	2013-11-06	Sanofi Sa	Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DK3682905T3 (da)	2011-10-03	2022-02-28	Modernatx Inc	Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
RS63948B1 (sr) *	2011-10-31	2023-02-28	Hoffmann La Roche	Formulacije anti-il13 antitela
KR101483335B1 (ko)	2011-11-01	2015-01-15	울산대학교 산학협력단	골 손실 진단 마커로서의 피브리노겐의 용도
DE12858350T1 (de)	2011-12-16	2021-10-07	Modernatx, Inc.	Modifizierte mrna zusammensetzungen
EP3725892A1 (en) *	2012-03-27	2020-10-21	F. Hoffmann-La Roche AG	Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
HK1206601A1 (en)	2012-04-02	2016-01-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
CA2878856A1 (en) *	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating car t cells
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
EP2830651A4 (en)	2013-03-12	2015-09-02	Abbvie Inc	HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2981286A4 (en) *	2013-04-05	2016-08-24	Hoffmann La Roche	ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
ES2915378T3 (es)	2013-09-13	2022-06-22	Hoffmann La Roche	Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102571391B1 (ko)	2013-09-13	2023-08-29	제넨테크, 인크.	정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3052640A2 (en)	2013-10-04	2016-08-10	AbbVie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
MX2016010729A (es)	2014-02-21	2016-10-26	Genentech Inc	Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
KR20160138095A (ko) *	2014-04-11	2016-12-02	노파르티스 아게	Il-13 길항제를 사용하여 천식을 선택적으로 치료하는 방법
CN106471117A (zh)	2014-05-06	2017-03-01	豪夫迈·罗氏有限公司	使用哺乳动物细胞产生异多聚体蛋白
EP3158077B1 (en) *	2014-06-18	2023-04-05	Medimmune, LLC	Cell culture methods and media comprising n-acetylcysteine
CN108064308B (zh)	2014-11-05	2023-06-09	豪夫迈·罗氏有限公司	细菌中产生双链蛋白的方法
RU2739500C2 (ru)	2014-11-05	2020-12-25	Дженентек, Инк.	Способы получения двуцепочечных белков в бактериях
US20160168640A1 (en)	2014-11-10	2016-06-16	Genentech, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
MX2017006094A (es)	2014-11-10	2017-07-19	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos.
CA2977285A1 (en) *	2015-03-16	2016-09-22	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
CA2980189A1 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
CN115932273A (zh)	2015-04-24	2023-04-07	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
KR102460040B1 (ko)	2016-04-27	2022-11-01	애브비 인코포레이티드	항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
HRP20231015T1 (hr)	2016-09-23	2023-12-08	F. Hoffmann-La Roche Ag	Upotreba antagonista il-13 u liječenju atopičnog dermatitisa
US10610104B2 (en)	2016-12-07	2020-04-07	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
TWI778018B (zh)	2017-02-10	2022-09-21	美商建南德克公司	抗類胰蛋白酶抗體、其組合物及其用途
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
AU2018254542B2 (en)	2017-04-21	2022-12-22	Elanco Us Inc.	IL4/IL13 receptor molecule for veterinary use
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN109776677B (zh) *	2017-11-15	2023-11-03	尚华科创投资管理（江苏）有限公司	一种人源化抗il-13抗体及其制备方法和应用
CN113101364B (zh)	2018-05-29	2023-12-01	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制剂的开发和应用
WO2020006486A1 (en) *	2018-06-29	2020-01-02	Krystal Biotech, Inc.	Compositions and methods for antibody delivery
WO2020014650A1 (en) *	2018-07-13	2020-01-16	Memorial Sloan Kettering Cancer Center	Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
EP3870601A4 (en)	2018-10-25	2022-07-13	Kindred Biosciences, Inc.	IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
WO2020106757A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020180727A1 (en)	2019-03-06	2020-09-10	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
WO2020191346A1 (en)	2019-03-21	2020-09-24	Regeneron Pharmaceuticals, Inc.	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
KR20220005568A (ko) *	2019-05-09	2022-01-13	제넨테크, 인크.	항체의 제조 방법
US12329760B2 (en) *	2019-05-10	2025-06-17	The Trustees Of The University Of Pennsylvania	Methods and compositions for targeting retinoic acid for solid tumor immunotherapy
JP7551744B2 (ja)	2019-10-15	2024-09-17	イーライリリーアンドカンパニー	組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
EP4118114A1 (en)	2020-03-13	2023-01-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
KR20230005880A (ko) *	2020-04-22	2023-01-10	킨드레드 바이오사이언시스, 인코포레이티드	수의학적 사용을 위한 il4/il13 수용체 분자
TWI847170B (zh)	2021-07-16	2024-07-01	美商德米拉股份有限公司	用於治療異位性皮炎之il-13抗體
TWI859566B (zh)	2021-08-13	2024-10-21	美商德米拉股份有限公司	用於治療異位性皮膚炎之il-13抗體
WO2023044313A1 (en)	2021-09-15	2023-03-23	Dermira, Inc.	Il-13 inhibitors for the treatment of prurigo nodularis
WO2023130010A1 (en)	2021-12-30	2023-07-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
IL316174A (en) *	2022-04-26	2024-12-01	Novartis Ag	Multiple specific antibodies targeting IL-13 and IL-18
CU20250005A7 (es)	2022-06-17	2025-11-05	Apogee Biologics Inc	Anticuerpos que se unen a interleuquina 13
CN118005784A (zh) *	2022-11-08	2024-05-10	上海洛启生物医药技术有限公司	抗il-13长效纳米抗体序列及其应用
CN120826237A (zh)	2023-03-08	2025-10-21	德米拉公司	Il-13抗体用于治疗特应性皮炎
WO2024264003A2 (en) *	2023-06-22	2024-12-26	Paragon Therapeutics, Inc.	Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
TW202525846A (zh)	2023-08-25	2025-07-01	美商普羅特歐拉吉克適美國公司	抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025128984A1 (en)	2023-12-14	2025-06-19	Dermira, Inc.	Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
WO2025128990A1 (en)	2023-12-14	2025-06-19	Dermira, Inc.	Il-13 antibodies for the treatment of perennial allergic rhinitis
WO2025137523A2 (en)	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical formulations of antibodies that bind interleukin 13
US20250230251A1 (en)	2023-12-20	2025-07-17	Bristol-Myers Squibb Company	Antibodies targeting il-18 receptor beta (il-18rb) and related methods
TW202535935A (zh)	2023-12-20	2025-09-16	美商艾普吉醫療股份有限公司	結合介白素13之抗體之醫藥組合物
WO2025184453A1 (en)	2024-03-01	2025-09-04	Dermira, Inc.	Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin
CN121135878A (zh)	2024-06-14	2025-12-16	康诺亚生物医药科技（成都）有限公司	针对ox40l和il-13的双特异性抗体及其用途

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
DE3127674A1 (de)	1981-07-14	1983-02-24	Rheinmetall GmbH, 4000 Düsseldorf	Verfahren und vorrichtung zum belegen einer zielflaeche mit munition
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
WO1989004838A1 (en)	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
WO1989012624A2 (en)	1988-06-14	1989-12-28	Cetus Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5359037A (en)	1988-09-12	1994-10-25	Yeda Research And Development Co. Ltd.	Antibodies to TNF binding protein I
AU643427B2 (en)	1988-10-31	1993-11-18	Immunex Corporation	Interleukin-4 receptors
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5011778A (en)	1989-05-23	1991-04-30	Otsuka Pharmaceutical Co., Ltd.	Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
DE69029036T2 (de)	1989-06-29	1997-05-22	Medarex Inc	Bispezifische reagenzien für die aids-therapie
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
DE69026627T2 (de)	1989-12-20	1996-08-22	Schering Corp., Kenilworth, N.J.	Antikörperantagonisten gegen humanes interleukin-4
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en)	1990-03-20	2003-02-11	Sherie L. Morrison	Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0553235A1 (en)	1990-10-01	1993-08-04	The University Of Connecticut	Targeting viruses and cells for selective internalization by cells
EP0553244B8 (en)	1990-10-05	2005-06-08	Celldex Therapeutics, Inc.	Targeted immunostimulation with bispecific reagents
ATE160379T1 (de)	1990-10-29	1997-12-15	Chiron Corp	Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DK0574395T3 (da)	1990-11-09	2002-10-07	Stephen D Gillies	Cytokin-immunkonjugater
DE69206301T2 (de)	1991-03-29	1996-06-13	Sanofi, Paris	Protein mit der Aktivität vom Typ von Cytokin, dafür kodierende rekombinante DNS, transformierte Zellen und Mikroorganismen.
DK0511011T3 (da)	1991-04-26	1997-03-10	Surface Active Ltd	Nye antistoffer og fremgangsmåde til anvendelse heraf
JPH06510524A (ja)	1991-05-14	1994-11-24	ユニバーシティオブコネチカット	免疫原性タンパク質をコードする遺伝子の標的への配達
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
JPH06510278A (ja)	1991-06-05	1994-11-17	ユニバーシティオブコネチカット	分泌タンパク質をコードする遺伝子の標的への配達
US5965709A (en)	1991-08-14	1999-10-12	Genentech, Inc.	IgE antagonists
US5994514A (en)	1991-08-14	1999-11-30	Genentech, Inc.	Immunoglobulin variants
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
WO1993011236A1 (en)	1991-12-02	1993-06-10	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU3434393A (en)	1992-01-17	1993-08-03	Regents Of The University Of Michigan, The	Targeted virus
WO1993015766A1 (en)	1992-02-10	1993-08-19	Seragen, Inc.	Desensitization to specific allergens
AU3737893A (en)	1992-03-05	1993-10-05	Board Of Regents, The University Of Texas System	Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
EP0633943A4 (en)	1992-04-03	1997-05-02	Alexander T Young	GENTHERAPY USING TARGETED VIRAL VECTORS.
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5318564A (en)	1992-05-01	1994-06-07	Hemostatic Surgery Corporation	Bipolar surgical snare and methods of use
WO1993025788A1 (en)	1992-06-09	1993-12-23	Hoppe Ag	Latch and lockset system
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
WO1994004680A1 (en)	1992-08-21	1994-03-03	Schering Corporation	Human interleukin-13
US5596072A (en)	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
CN1085953A (zh) *	1992-08-21	1994-04-27	先灵公司	人白细胞介素13
CA2141602A1 (en)	1992-08-26	1994-03-03	Philip Leder	Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
ES2157225T3 (es)	1992-10-09	2001-08-16	Advanced Tissue Sciences Inc	Celulas hepaticas de reserva.
JPH08503855A (ja)	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	嚢胞性線維症に対する遺伝子治療
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
EP0604693A1 (en)	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ES2162863T3 (es)	1993-04-29	2002-01-16	Unilever Nv	Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
ATE188487T1 (de)	1993-09-02	2000-01-15	Dartmouth College	Anti-gp39 antikoerper und deren verwendungen
RU2162711C2 (ru) *	1993-09-07	2001-02-10	Смитклайн Бичам Корпорейшн	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
EP0659766A1 (en)	1993-11-23	1995-06-28	Schering-Plough	Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en)	1994-07-29	1994-09-21	Smithkline Beecham Plc	Novel compounds
IT1270662B (it) *	1994-10-13	1997-05-07	Applied Research Systems	Antagonista della interleuchina-1
US5705154A (en)	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US6518061B1 (en) *	1995-03-15	2003-02-11	The United States Of America As Represented By The Department Of Health And Human Services	IL-13 receptor specific chimeric proteins and uses thereof
US6037453A (en)	1995-03-15	2000-03-14	Genentech, Inc.	Immunoglobulin variants
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ES2317646T3 (es)	1995-09-08	2009-04-16	Genzyme Corporation	Vectores aav mejorados para terapia genica.
JP4224135B2 (ja)	1995-10-23	2009-02-12	ズィナイスセラピューティックスピーティーワイ．エルティーディー．	新規なヘモポエチン受容体およびそれをコードする遺伝子配列
US6911530B1 (en)	1995-10-23	2005-06-28	Amrad Operations, Pty., Ltd.	Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr)	1995-12-06	1997-06-13	Sanofi Sa	Polypeptide recepteur de l'il-13
BRPI9707379C8 (pt)	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5710023A (en)	1996-03-01	1998-01-20	Genetics Institute, Inc.	IL-13 cytokine receptor chain
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en)	1996-03-01	2006-07-18	Genetics Institute, Llc	Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
KR100497017B1 (ko)	1996-03-22	2005-11-29	휴먼 게놈 사이언시즈, 인코포레이티드	고사유도분자ii
WO1997047742A1 (en)	1996-06-12	1997-12-18	Smithkline Beecham Corporation	Hr-1 receptor
WO1998010638A1 (en)	1996-09-10	1998-03-19	Amrad Operations Pty. Ltd.	Therapeutic molecules
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
GB9625899D0 (en)	1996-12-13	1997-01-29	Glaxo Group Ltd	Substances and their uses
US6743604B1 (en)	1996-12-13	2004-06-01	Smithkline Beecham Corporation	Substances and their uses
CA2277222A1 (en)	1997-01-10	1998-07-16	Biogen, Inc.	Treatment of lupus nephritis with anti-cd40l compounds
EP0988056B1 (en) *	1997-01-22	2003-07-09	Board Of Regents, The University Of Texas System	Tissue factor methods and compositions for coagulation and tumor treatment
CN100387621C (zh)	1997-04-14	2008-05-14	麦可麦脱股份公司	抗人抗原受体的新的生产方法及其用途
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6642051B1 (en)	1997-10-21	2003-11-04	Targeted Genetics Corporation	Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
CA2309541C (en)	1997-11-03	2011-01-11	Human Genome Sciences, Inc.	Vegi, an inhibitor of angiogenesis and tumor growth
US6576232B1 (en)	1998-04-03	2003-06-10	The Penn State Research Foundation	IL13 mutants
US6482403B1 (en)	1998-05-29	2002-11-19	Heska Corporation	Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en)	1998-06-04	2001-10-09	Panacea Pharmaceuticals, Llc	Methods to block IGE binding to cell surface receptors of mast cells
US6222971B1 (en)	1998-07-17	2001-04-24	David Slobodin	Small inlet optical panel and a method of making a small inlet optical panel
GB9820014D0 (en)	1998-09-14	1998-11-04	Cancer Res Campaign Tech	Receptor antagonists and uses thereof
DE19848026A1 (de)	1998-10-17	2000-04-20	Bayer Ag	Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
US7553487B2 (en)	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
WO2000036103A1 (en)	1998-12-14	2000-06-22	Genetics Institute, Inc.	Cytokine receptor chain
WO2000044074A1 (en)	1999-01-26	2000-07-27	California Institute Of Technology	Opto-electronic oscillators having optical resonators
WO2000044407A2 (en)	1999-02-01	2000-08-03	Amgen Canada	Materials and methods to inhibit hodgkin and reed sternberg cell growth
EP1222212A4 (en) *	1999-10-06	2005-05-04	Penn State Res Found	MUTANTS OF IL-13
WO2001034645A2 (en)	1999-11-11	2001-05-17	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Mutated il-13 molecules and their uses
US7422376B2 (en)	1999-12-07	2008-09-09	Molex Incorporated	Self-contained fiber optic connector module
US6989145B2 (en)	2000-03-03	2006-01-24	Kyowa Hakko Kogyo Co., Ltd.	Recombinant antibody and antibody fragment
CN1323812A (zh)	2000-05-16	2001-11-28	上海博德基因开发有限公司	一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
ES2311558T3 (es)	2000-10-20	2009-02-16	Genetics Institute, Inc.	Uso de inhibidores de la il-13 para el tratamiento de tumores.
AU2002210918B2 (en)	2000-10-20	2006-03-16	Chugai Seiyaku Kabushiki Kaisha	Degraded agonist antibody
CN100430420C (zh) *	2001-08-31	2008-11-05	协和发酵工业株式会社	人cdr-移植抗体及其抗体片段
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1578912A4 (en)	2001-10-26	2007-12-26	Centocor Inc	IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
PL369863A1 (en)	2001-11-07	2005-05-02	Cytos Biotechnology Ag	Antigen arrays for treatment of allergic eosinophilic diseases
WO2003047632A1 (en) *	2001-12-04	2003-06-12	The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health	Chimeric molecule for the treatment of th2-like cytokine mediated disorders
US20030170724A1 (en) *	2002-03-08	2003-09-11	Anderson David C.	Methods of identifying target polypeptides
WO2003075859A2 (en) *	2002-03-08	2003-09-18	Rigel Pharmaceuticals, Inc.	COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME
WO2003086451A1 (en)	2002-04-05	2003-10-23	Centocor, Inc.	Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
ATE503233T1 (de)	2002-06-14	2011-04-15	Us Gov Health & Human Serv	Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
US7374894B2 (en) *	2002-07-16	2008-05-20	Rigel Pharmaceuticals, Inc.	Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
CA2496409A1 (en)	2002-08-30	2004-03-11	Glaxo Group Limited	Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
WO2004019975A2 (en)	2002-08-30	2004-03-11	Glaxo Group Limited	Il-14 vaccine for the treatment of asthma and atopic disorders
US7438910B2 (en) *	2002-09-06	2008-10-21	Amgen Inc.	Therapeutic human anti-IL1-R1 monoclonal antibody
EP1592777A4 (en)	2003-02-01	2008-06-04	Tanox Inc	METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
ES2257616T3 (es) *	2003-04-25	2006-08-01	Actimis Pharmaceuticals, Inc.	Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
GB0407315D0 (en) *	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
DK3718564T3 (da) *	2003-12-23	2023-11-06	Genentech Inc	Nye anti-IL-13-antistoffer og anvendelser
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
WO2007036745A2 (en)	2005-09-30	2007-04-05	Medimmune Limited	Interleukin-13 antibody composition
EP1957530A2 (en)	2005-10-21	2008-08-20	Novartis AG	Human antibodies against il13 and therapeutic uses
WO2008140455A1 (en)	2007-05-15	2008-11-20	Tanox, Inc.	Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
CN102232113A (zh)	2008-03-31	2011-11-02	健泰科生物技术公司	用于治疗和诊断哮喘的组合物和方法
EP3447491A3 (en)	2010-12-16	2019-06-05	F. Hoffmann-La Roche AG	Diagnosis and treatments relating to th2 inhibition

2004
- 2004-12-23 DK DK20155148.8T patent/DK3718564T3/da active
- 2004-12-23 SG SG10201404273QA patent/SG10201404273QA/en unknown
- 2004-12-23 CN CNA2004800388204A patent/CN1898264A/zh active Pending
- 2004-12-23 CN CN201410077001.6A patent/CN104013957B/zh not_active Expired - Lifetime
- 2004-12-23 KR KR1020147003706A patent/KR101627588B1/ko not_active Expired - Lifetime
- 2004-12-23 WO PCT/US2004/043541 patent/WO2005062972A2/en not_active Ceased
- 2004-12-23 ES ES14164624T patent/ES2775204T3/es not_active Expired - Lifetime
- 2004-12-23 PT PT04815562T patent/PT1703893E/pt unknown
- 2004-12-23 AU AU2004308494A patent/AU2004308494B2/en active Active
- 2004-12-23 FI FIEP20155148.8T patent/FI3718564T3/fi active
- 2004-12-23 SI SI200431888T patent/SI1703893T1/sl unknown
- 2004-12-23 SG SG10201900535UA patent/SG10201900535UA/en unknown
- 2004-12-23 ES ES04815598T patent/ES2390344T3/es not_active Expired - Lifetime
- 2004-12-23 SI SI200432525T patent/SI3718564T1/sl unknown
- 2004-12-23 PT PT141646240T patent/PT2805728T/pt unknown
- 2004-12-23 PL PL14164624T patent/PL2805728T3/pl unknown
- 2004-12-23 KR KR1020157014126A patent/KR20150064250A/ko not_active Ceased
- 2004-12-23 PL PL04815598T patent/PL1711528T3/pl unknown
- 2004-12-23 US US10/583,926 patent/US7674459B2/en active Active
- 2004-12-23 RU RU2006122037/10A patent/RU2487887C2/ru active
- 2004-12-23 ES ES10179775.1T patent/ES2533084T3/es not_active Expired - Lifetime
- 2004-12-23 SI SI200432492T patent/SI2805728T1/sl unknown
- 2004-12-23 EP EP20155148.8A patent/EP3718564B1/en not_active Expired - Lifetime
- 2004-12-23 WO PCT/US2004/043501 patent/WO2005062967A2/en not_active Ceased
- 2004-12-23 JP JP2006547431A patent/JP4851944B2/ja not_active Expired - Lifetime
- 2004-12-23 EP EP10178487A patent/EP2351584A1/en not_active Withdrawn
- 2004-12-23 US US10/583,927 patent/US8067199B2/en not_active Expired - Lifetime
- 2004-12-23 KR KR1020127001379A patent/KR20120020203A/ko not_active Ceased
- 2004-12-23 KR KR1020137007978A patent/KR20130041373A/ko not_active Ceased
- 2004-12-23 EP EP04815562A patent/EP1703893B1/en not_active Expired - Lifetime
- 2004-12-23 SG SG2012070413A patent/SG184774A1/en unknown
- 2004-12-23 PT PT201551488T patent/PT3718564T/pt unknown
- 2004-12-23 SG SG200901976-1A patent/SG151296A1/en unknown
- 2004-12-23 CA CA2550651A patent/CA2550651C/en not_active Expired - Lifetime
- 2004-12-23 HU HUE20155148A patent/HUE064610T2/hu unknown
- 2004-12-23 ES ES20155148T patent/ES2967485T3/es not_active Expired - Lifetime
- 2004-12-23 EP EP10179775.1A patent/EP2332575B1/en not_active Expired - Lifetime
- 2004-12-23 DK DK14164624.0T patent/DK2805728T3/da active
- 2004-12-23 PL PL20155148.8T patent/PL3718564T3/pl unknown
- 2004-12-23 KR KR1020067014859A patent/KR101280338B1/ko not_active Expired - Lifetime
- 2004-12-23 LT LTEP20155148.8T patent/LT3718564T/lt unknown
- 2004-12-23 ES ES04815562T patent/ES2385038T3/es not_active Expired - Lifetime
- 2004-12-23 MX MX2015002420A patent/MX361174B/es unknown
- 2004-12-23 AT AT04815562T patent/ATE552850T1/de active
- 2004-12-23 CN CN2004800386571A patent/CN1973053B/zh not_active Expired - Lifetime
- 2004-12-23 HR HRP20120376TT patent/HRP20120376T1/hr unknown
- 2004-12-23 CA CA2551110A patent/CA2551110C/en not_active Expired - Lifetime
- 2004-12-23 DK DK04815562.6T patent/DK1703893T3/da active
- 2004-12-23 SI SI200431935T patent/SI1711528T1/sl unknown
- 2004-12-23 EP EP04815598A patent/EP1711528B1/en not_active Expired - Lifetime
- 2004-12-23 EP EP14164624.0A patent/EP2805728B1/en not_active Expired - Lifetime
- 2004-12-23 DK DK04815598.0T patent/DK1711528T3/da active
- 2004-12-23 HU HUE14164624A patent/HUE049161T2/hu unknown
- 2004-12-23 JP JP2006547441A patent/JP4943161B2/ja not_active Expired - Lifetime
- 2004-12-23 PL PL04815562T patent/PL1703893T3/pl unknown
- 2004-12-23 HR HRP20231569TT patent/HRP20231569T1/hr unknown
- 2004-12-23 LT LTEP14164624.0T patent/LT2805728T/lt unknown
- 2004-12-23 CN CN201210299210.6A patent/CN102993302B/zh not_active Expired - Lifetime
2006
- 2006-05-31 IL IL176042A patent/IL176042A/en active IP Right Grant
2007
- 2007-01-25 JP JP2007015642A patent/JP2007161724A/ja active Pending
2008
- 2008-09-29 US US12/240,604 patent/US8088618B2/en active Active
2010
- 2010-01-14 US US12/687,637 patent/US8318160B2/en not_active Expired - Lifetime
- 2010-10-15 JP JP2010233095A patent/JP2011042669A/ja active Pending
2011
- 2011-05-18 JP JP2011111913A patent/JP2011200242A/ja not_active Withdrawn
- 2011-10-18 US US13/275,684 patent/US8734801B2/en not_active Expired - Lifetime
- 2011-10-18 US US13/275,658 patent/US8734797B2/en not_active Expired - Lifetime
- 2011-11-30 US US13/308,186 patent/US9067994B2/en not_active Expired - Lifetime
2012
- 2012-05-31 CY CY20121100496T patent/CY1113009T1/el unknown
- 2012-06-05 RU RU2012123148/10A patent/RU2012123148A/ru unknown
2013
- 2013-08-20 US US13/971,394 patent/US9605065B2/en active Active
2014
- 2014-04-23 IL IL232210A patent/IL232210A0/en unknown
2017
- 2017-09-29 US US15/721,570 patent/US20180251538A1/en not_active Abandoned
2019
- 2019-11-13 US US16/682,773 patent/US11434287B2/en not_active Expired - Lifetime
2020
- 2020-02-13 RU RU2020106818A patent/RU2752833C1/ru active
- 2020-04-14 HR HRP20200592TT patent/HRP20200592T1/hr unknown
- 2020-04-28 CY CY20201100385T patent/CY1122817T1/el unknown

Also Published As

Publication number	Publication date
ES2533084T3 (es)	2015-04-07
EP2805728A1 (en)	2014-11-26
WO2005062967A2 (en)	2005-07-14
WO2005062972A3 (en)	2005-10-13
CN1973053B (zh)	2012-10-10
MX361174B (es)	2018-11-29
KR20140025614A (ko)	2014-03-04
KR20120020203A (ko)	2012-03-07
US9605065B2 (en)	2017-03-28
JP4851944B2 (ja)	2012-01-11
KR20150064250A (ko)	2015-06-10
US20120164144A1 (en)	2012-06-28
EP2351584A1 (en)	2011-08-03
ES2390344T3 (es)	2012-11-12
EP1703893A4 (en)	2008-04-02
US20140105897A1 (en)	2014-04-17
DK1703893T3 (da)	2012-05-07
ES2385038T3 (es)	2012-07-17
HUE064610T2 (hu)	2024-04-28
CN102993302B (zh)	2016-01-20
CA2550651C (en)	2018-01-23
CA2551110A1 (en)	2005-07-14
EP1711528A4 (en)	2007-07-11
SI3718564T1 (sl)	2024-01-31
EP2332575A1 (en)	2011-06-15
CN104013957B (zh)	2016-06-29
DK1711528T3 (da)	2012-08-20
AU2004308494A1 (en)	2005-07-14
FI3718564T3 (fi)	2023-12-15
JP2011042669A (ja)	2011-03-03
ATE552850T1 (de)	2012-04-15
US8734797B2 (en)	2014-05-27
HK1201457A1 (en)	2015-09-04
SG151296A1 (en)	2009-04-30
KR20130041373A (ko)	2013-04-24
RU2752833C1 (ru)	2021-08-09
SI1711528T1 (sl)	2012-10-30
KR101280338B1 (ko)	2013-07-09
CY1113009T1 (el)	2016-04-13
DK3718564T3 (da)	2023-11-06
JP2011200242A (ja)	2011-10-13
JP2007161724A (ja)	2007-06-28
CN102993302A (zh)	2013-03-27
US20120214971A1 (en)	2012-08-23
IL176042A (en)	2014-04-30
ES2967485T3 (es)	2024-04-30
US20200291106A1 (en)	2020-09-17
JP4943161B2 (ja)	2012-05-30
AU2004308494B2 (en)	2010-03-18
PT3718564T (pt)	2023-11-23
US20090214523A1 (en)	2009-08-27
LT3718564T (lt)	2023-12-11
EP2805728B1 (en)	2020-02-05
US8088618B2 (en)	2012-01-03
EP1703893B1 (en)	2012-04-11
JP2007537146A (ja)	2007-12-20
US7674459B2 (en)	2010-03-09
HUE049161T2 (hu)	2020-09-28
HRP20120376T1 (hr)	2012-05-31
PL3718564T3 (pl)	2024-03-18
DK2805728T3 (da)	2020-04-20
CN104013957A (zh)	2014-09-03
ES2775204T3 (es)	2020-07-24
HK1204288A1 (en)	2015-11-13
IL232210A0 (en)	2014-05-28
US8067199B2 (en)	2011-11-29
PL1703893T3 (pl)	2012-09-28
US11434287B2 (en)	2022-09-06
PL2805728T3 (pl)	2020-07-13
KR20060130625A (ko)	2006-12-19
US20080008648A1 (en)	2008-01-10
HRP20200592T1 (hr)	2020-08-07
CN1973053A (zh)	2007-05-30
US8318160B2 (en)	2012-11-27
CA2551110C (en)	2016-01-19
US20120156203A1 (en)	2012-06-21
CN1898264A (zh)	2007-01-17
IL176042A0 (en)	2006-10-05
PL1711528T3 (pl)	2012-11-30
CA2550651A1 (en)	2005-07-14
US20110014199A1 (en)	2011-01-20
HK1108007A1 (en)	2008-04-25
RU2006122037A (ru)	2008-01-27
SG10201404273QA (en)	2014-10-30
EP1711528B1 (en)	2012-07-18
RU2012123148A (ru)	2013-12-10
SG184774A1 (en)	2012-10-30
JP2008500024A (ja)	2008-01-10
SI2805728T1 (sl)	2020-07-31
EP1703893A2 (en)	2006-09-27
KR101627588B1 (ko)	2016-06-07
EP2332575B1 (en)	2014-11-12
CY1122817T1 (el)	2021-05-05
RU2487887C2 (ru)	2013-07-20
US20180251538A1 (en)	2018-09-06
EP3718564B1 (en)	2023-10-11
WO2005062967A3 (en)	2006-12-21
LT2805728T (lt)	2020-05-25
PT1703893E (pt)	2012-06-01
PT2805728T (pt)	2020-04-08
EP3718564A1 (en)	2020-10-07
HRP20231569T1 (hr)	2024-03-15
EP1711528A2 (en)	2006-10-18
WO2005062972A2 (en)	2005-07-14
US8734801B2 (en)	2014-05-27
SG10201900535UA (en)	2019-02-27
US20100266494A1 (en)	2010-10-21
US9067994B2 (en)	2015-06-30

Publication	Publication Date	Title
IL232210A0 (en)	2014-05-28	New anti-13 il antibodies and their uses
MY144906A (en)	2011-11-30	Human antibodies against il13 and therapeutic uses
WO2007036745A3 (en)	2007-08-02	Interleukin-13 antibody composition
TW200612985A (en)	2006-05-01	Immunoglobulins
MX2009010765A (es)	2009-10-26	Anticuerpos anti-ige.
WO2010021874A3 (en)	2016-03-24	Engineered anti-il-13 antibodies, compositions, methods and uses
WO2008134659A8 (en)	2009-04-23	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
TW200503721A (en)	2005-02-01	Aminoquinoline compounds
NZ600584A (en)	2014-05-30	Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
MY159370A (en)	2016-12-30	Semi-soft-class immunostimulatory oligonucleotides
IL171356A (en)	2010-11-30	Anti-interferon receptor antibody for treatment of inflammatory bowel disease
MX2007003031A (es)	2007-05-23	Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
EP1558766A4 (en)	2007-12-26	USE OF A33 ANTIGENES AND JAM IT
WO2004024098A3 (en)	2004-07-01	Method for the treatment of nephritis using anti-pdgf-dd antibodies
WO2002081745A3 (en)	2003-10-23	Genes involved in osteogenesis, and methods of use
TNSN08175A1 (en)	2009-10-30	Human antibodies against il-13 and therapeutic uses
ATE496047T1 (de)	2011-02-15	Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien